Relief as new bowel cancer drugs announced
Years of advocacy from Bowel Cancer New Zealand (NZ) and other groups calling for new bowel cancer drugs has led to a funding from Pharmac for two new medicines, cetuximab (Erbitux) and pembrolizumab (Keytruda).
“This is fantastic news and acknowledgement of all the hard mahi by our bowel cancer community. We celebrate this milestone while also acknowledging all those who bravely fought alongside us and aren’t here today,” says Rebekah Heal, general manager of Bowel Cancer NZ.
In July 2024, the government boosted Pharmac funding, with an extra $604 million guaranteed over the next four years towards 54 new drugs, including the first bowel cancer medicines funded in over 20 years. “This will help relieve some of the enormous financial burden so many bowel cancer patients are shouldering,” says Rebekah. “It’s also evident just how underfunded Pharmac has been until now.”
Keytruda will be available from 1 October as a funded treatment option for Lynch Syndrome bowel cancer patients. A date has yet to be set for cetuximab, although it was listed as one of the drugs to be funded in the next year.
While cetuximab will be funded, this does not currently include bowel cancers with the BRAF mutation. Bowel Cancer NZ wants to see funding extended and expedited for patients with this mutation, like Blair Vining, who passed away in 2019.
Cancer advocate Melissa Vining says, “For many patients like Blair with a BRAF mutation, this is heartbreaking news. Facing an aggressive form of cancer with no publicly funded drugs available leaves you with several choices: leave NZ to obtain treatment in Australia, fundraise for the treatment, sell your home if you have one or wait to die knowing that if you lived in a comparable country like Australia, your treatment would be funded. This takes an incredible toll on many New Zealanders who simply deserve a fair chance at treatment.”
This progress in funding bowel cancer drugs is encouraging, but there’s still more to be done. Bowel Cancer NZ continues to advocate for bevacizumab (Avastin), which has been on the Medicine Waiting List since 2010.
